These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 19187624)

  • 1. Human immunodeficiency virus and hepatitis C virus co-infection: epidemiology, natural history and the situation in China.
    Lu Y; Robinson M; Zhang FJ
    Chin Med J (Engl); 2009 Jan; 122(1):93-7. PubMed ID: 19187624
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment with pegylated interferon and ribavirin in patients co-infected by human immunodeficiency virus and hepatitis C virus].
    Marcos Sánchez F; Albo Castaño MI; Casallo Blanco S
    Rev Clin Esp; 2007 Mar; 207(3):150-1; author reply 151-2. PubMed ID: 17397643
    [No Abstract]   [Full Text] [Related]  

  • 3. Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients.
    Sherman KE; Shire NJ; Rouster SD; Peters MG; James Koziel M; Chung RT; Horn PS
    Gastroenterology; 2005 Feb; 128(2):313-27. PubMed ID: 15685543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Care of patients with hepatitis C and HIV co-infection.
    Soriano V; Puoti M; Sulkowski M; Mauss S; Cacoub P; Cargnel A; Dieterich D; Hatzakis A; Rockstroh J
    AIDS; 2004 Jan; 18(1):1-12. PubMed ID: 15090824
    [No Abstract]   [Full Text] [Related]  

  • 5. HIV and hepatitis co-infection: a consensus for treatment?
    Lumb J
    Lancet Infect Dis; 2005 Apr; 5(4):202. PubMed ID: 15834972
    [No Abstract]   [Full Text] [Related]  

  • 6. Sexually transmitted reinfection with a new hepatitis C genotype during pegylated interferon and ribavirin therapy.
    den Hollander JG; Rijnders BJ; van Doornum GJ; van der Ende ME
    AIDS; 2005 Mar; 19(6):639-40. PubMed ID: 15802989
    [No Abstract]   [Full Text] [Related]  

  • 7. Ribavirin plasma concentration predicts sustained virological response to peginterferon Alfa 2a plus ribavirin in previously treated HCV-HIV-coinfected patients.
    Breilh D; Djabarouti S; Trimoulet P; Le Bail B; Dupon M; Ragnaud JM; Fleury H; Saux MC; Thiébaut R; Chêne G; Neau D
    J Acquir Immune Defic Syndr; 2009 Nov; 52(3):428-30. PubMed ID: 19858925
    [No Abstract]   [Full Text] [Related]  

  • 8. HCV infection in the setting of HIV: prevalence, disease, treatment.
    Laurence J
    AIDS Read; 2006 Mar; 16(3):115-6. PubMed ID: 16538952
    [No Abstract]   [Full Text] [Related]  

  • 9. [HIV/HCV double infection: combination is a clear therapy option].
    Reich B
    Dtsch Med Wochenschr; 2004 Jul; 129(28-29):1590. PubMed ID: 15274242
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of Eradication of HCV on Hepatic Venous Pressure Gradient in HIV-Infected Patients With Compensated HCV-Related Cirrhosis.
    Sánchez-Conde M; Pérez-Latorre L; Rincón D; Miralles P; Catalina MV; López JC; Bañares R; Berenguer J
    J Acquir Immune Defic Syndr; 2015 Aug; 69(4):e142-4. PubMed ID: 25861016
    [No Abstract]   [Full Text] [Related]  

  • 11. Pegylated interferon-alpha2a and ribavirin in HIV-hepatitis C coinfected patients.
    Expert Rev Anti Infect Ther; 2004 Jun; 2(3):341-2. PubMed ID: 15490503
    [No Abstract]   [Full Text] [Related]  

  • 12. Comment on Neumann et al. 'Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients'.
    D'Offizi G; Martini F; Rozera G; Abbate I; Capobianchi MR; Narciso P; Dianzani F
    AIDS; 2008 Jan; 22(2):321. PubMed ID: 18097242
    [No Abstract]   [Full Text] [Related]  

  • 13. FDA approves Pegasys and Copegus for hepatitis C in patients with HIV co-infection.
    Bartlett JG
    Hopkins HIV Rep; 2005 May; 17(3):15. PubMed ID: 16419314
    [No Abstract]   [Full Text] [Related]  

  • 14. Acute hepatitis C and HIV coinfection.
    Dionne-Odom J; Osborn MK; Radziewicz H; Grakoui A; Workowski K
    Lancet Infect Dis; 2009 Dec; 9(12):775-83. PubMed ID: 19926037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HBV plus HCV, HCV plus HIV, HBV plus HIV.
    Park JS; Saraf N; Dieterich DT
    Curr Gastroenterol Rep; 2006 Feb; 8(1):67-74. PubMed ID: 16510037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. UNITAID can address HCV/HIV co-infection.
    von Schoen-Angerer T; Cohn J; Swan T; Piot P
    Lancet; 2013 Feb; 381(9867):628. PubMed ID: 23439101
    [No Abstract]   [Full Text] [Related]  

  • 17. Rate and timing of hepatitis C virus relapse after a successful course of pegylated interferon plus ribavirin in HIV-infected and HIV-uninfected patients.
    Medrano J; Barreiro P; Resino S; Tuma P; Rodríguez V; Vispo E; Labarga P; Madejón A; García-Samaniego J; Jiménez-Nácher I; Martín-Carbonero L; Soriano V
    Clin Infect Dis; 2009 Nov; 49(9):1397-401. PubMed ID: 19814621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Super-infection with genotype 4 hepatitis C virus in a patient treated for genotype 3 acute hepatitis C.
    Loulergue P; Mir O; Sogni P
    AIDS; 2012 Mar; 26(5):655-6. PubMed ID: 22398573
    [No Abstract]   [Full Text] [Related]  

  • 19. Cure of acute hepatitis C in HIV co-infection?
    Ristig MB; Tebas P; Gandy I; Qaqish R; Aberg JA
    J Clin Gastroenterol; 2004 Mar; 38(3):303. PubMed ID: 15128087
    [No Abstract]   [Full Text] [Related]  

  • 20. Delaying HCV treatment in HIV-positive patients.
    Carter M
    IAPAC Mon; 2005 May; 11(5):147. PubMed ID: 16201045
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.